<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35244505</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Reassembling of albumin-bound paclitaxel mitigates myelosuppression and improves its antitumoral efficacy via neutrophil-mediated targeting drug delivery.</ArticleTitle>
        <Pagination>
          <StartPage>728</StartPage>
          <EndPage>742</EndPage>
          <MedlinePgn>728-742</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2046892</ELocationID>
        <Abstract>
          <AbstractText>Albumin-bound paclitaxel (abPTX) has been widely used in cancer treatment. However, dose-related side effects, such as myelosuppression, restrict its clinical application. Cell-based targeting drug delivery is a promising way to mitigate systematic side-effects and improve antitumoral efficacy. In this study, we demonstrated that reassembled abPTX could be engulfed by neutrophils <i>in vivo</i> and delivered to tumor site, thus improving therapeutic efficacy and mitigating myelosuppression. First, <i>in vitro</i> analysis confirmed that reassembling of abPTX formed uniform and stable serum albumin nanoparticles (NP-abPTX) with size of 107.5 ± 2.29 nm and reserved the ability to kill tumor cells. Second, we found that NP-abPTX could be engulfed by activated neutrophil <i>in vitro</i> and <i>in vivo</i> but do not affect neutrophils' function, such as chemotaxis and activation. In a murine tumor model, we further proved that local radiotherapy (RT) induced inflammation activated peripheral neutrophils to capture venous infused NP-abPTX and carry them into tumor tissue. As compared to abPTX, infusion of NP-abPTX dramatically enhanced inhibition of tumor growth treated by local RT and mitigated hematotoxicity. Therefore, our study demonstrated a novel strategy to mitigate side-effects and to improve tumor killing efficacy of abPTX through neutrophil-mediated targeting drug delivery.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yuxin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Lulu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Xiaoyan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Meng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zheng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xin</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Yanfang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Ankang</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Animal Laboratory, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chai</LastName>
            <ForeName>Dafei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Liantao</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Huizhong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Junnian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-6020-7263</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000068196">Albumin-Bound Paclitaxel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000068196" MajorTopicYN="Y">Albumin-Bound Paclitaxel</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Albumin-bound paclitaxel (abPTX)</Keyword>
        <Keyword MajorTopicYN="N">NP-abPTX</Keyword>
        <Keyword MajorTopicYN="N">myelosuppression</Keyword>
        <Keyword MajorTopicYN="N">neutrophil-mediated drug delivery</Keyword>
        <Keyword MajorTopicYN="N">radiotherapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35244505</ArticleId>
        <ArticleId IdType="pmc">PMC8903760</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2046892</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bokoch G, Zhao T. (2006). Regulation of the phagocyte NADPH oxidase by Rac GTPase. Antioxid Redox Signal
8:1533–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16987009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinkmann V, Reichard U, Goosmann C, et al.  (2004). Neutrophil extracellular traps kill bacteria. Science
303:1532–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15001782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu D, Dong X, Zhao Q, et al.  (2017). Photosensitization priming of tumor microenvironments improves delivery of nanotherapeutics via neutrophil infiltration. Adv Mater
29:1701021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5510494</ArticleId>
            <ArticleId IdType="pubmed">28504320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu D, Gao J, Wang Z. (2015). Neutrophil-mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection. ACS Nano
9:11800–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4699556</ArticleId>
            <ArticleId IdType="pubmed">26516654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutiérrez Millán C, Colino Gandarillas C, Sayalero Marinero M, Lanao J. (2012). Cell-based drug-delivery platforms. Ther Deliv
3:25–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22833931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao J, Chen J, Wang M. (2020). Neutrophils, as "Trojan horses", participate in the delivery of therapeutical PLGA nanoparticles into a tumor based on the chemotactic effect. Drug Deliv
27:1–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6920705</ArticleId>
            <ArticleId IdType="pubmed">31818156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joerger M. (2016). Treatment regimens of classical and newer taxanes. Cancer Chemother Pharmacol
77:221–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26589792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju C, Wen Y, Zhang L, et al.  (2019). Neoadjuvant chemotherapy based on abraxane/human neutrophils cytopharmaceuticals with radiotherapy for gastric cancer. Small
15:e1804191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30549431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li YJ, Wu JY, Liu J, et al.  (2021). From blood to brain: blood cell-based biomimetic drug delivery systems. Drug Deliv
28:1214–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8259840</ArticleId>
            <ArticleId IdType="pubmed">34142628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naumenko V, Nikitin A, Garanina A, et al.  (2020). Neutrophil-mediated transport is crucial for delivery of short-circulating magnetic nanoparticles to tumors. Acta Biomater
104:176–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31945505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierige F, Serafini S, Rossi L, Magnani M. (2008). Cell-based drug delivery. Adv Drug Deliv Rev
60:286–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17997501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramadori G, Cameron S. (2010). Effects of systemic chemotherapy on the liver. Ann Hepatol
9:133–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20526005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowinsky E, Donehower R. (1995). Paclitaxel (taxol). N Engl J Med
332:1004–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7885406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith J. (1994). Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol
56:672–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7996043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder J, Nettles J, Cornett B, et al.  (2001). The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A
98:5312–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC33206</ArticleId>
            <ArticleId IdType="pubmed">11309480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Socinski M, Manikhas G, Stroyakovsky D, et al.  (2010). A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol
5:852–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20521351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Y, Xie Z, Kim GB, et al.  (2015). Design strategies and applications of circulating cell-mediated drug delivery systems. ACS Biomater Sci Eng
1:201–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4428174</ArticleId>
            <ArticleId IdType="pubmed">25984572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Superfin D, Iannucci AA, Davies AM. (2007). Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Oncologist
12:1070–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17914077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeshima T, Pop LM, Laine A, et al.  (2016). Key role for neutrophils in radiation-induced antitumor immune responses: potentiation with G-CSF. Proc Natl Acad Sci U S A
113:11300–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5056034</ArticleId>
            <ArticleId IdType="pubmed">27651484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan H, Hu J, Liu S. (2019). Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis. Artif Cells Nanomed Biotechnol
47:268–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30600739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timmerman R, Paulus R, Galvin J, et al.  (2010). Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA
303:1070–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2907644</ArticleId>
            <ArticleId IdType="pubmed">20233825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villanueva MT. (2017). Chemotherapy: neutrophils deliver the goods. Nat Rev Cancer
17:454–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28740115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang G, Cao L, Liu X, et al.  (2016). Oxidant sensing by TRPM2 inhibits neutrophil migration and mitigates inflammation. Dev Cell
38:453–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5455786</ArticleId>
            <ArticleId IdType="pubmed">27569419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Li J, Cho J, Malik A. (2014). Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils. Nat Nanotechnol
9:204–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4100792</ArticleId>
            <ArticleId IdType="pubmed">24561355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue J, Zhao Z, Zhang L, et al.  (2017). Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol
12:692–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28650441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaromina A, Krause M, Baumann M. (2012). Individualization of cancer treatment from radiotherapy perspective. Mol Oncol
6:211–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5528361</ArticleId>
            <ArticleId IdType="pubmed">22381063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Yang Z, Li F, et al.  (2020). Cell-mediated targeting drugs delivery systems. Drug Deliv
27:1425–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7594730</ArticleId>
            <ArticleId IdType="pubmed">33096949</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35244505</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1521-0464</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>29</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery</Title>
          <ISOAbbreviation>Drug Deliv</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Reassembling of albumin-bound paclitaxel mitigates myelosuppression and improves its antitumoral efficacy via neutrophil-mediated targeting drug delivery.</ArticleTitle>
        <Pagination>
          <StartPage>728</StartPage>
          <EndPage>742</EndPage>
          <MedlinePgn>728-742</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/10717544.2022.2046892</ELocationID>
        <Abstract>
          <AbstractText>Albumin-bound paclitaxel (abPTX) has been widely used in cancer treatment. However, dose-related side effects, such as myelosuppression, restrict its clinical application. Cell-based targeting drug delivery is a promising way to mitigate systematic side-effects and improve antitumoral efficacy. In this study, we demonstrated that reassembled abPTX could be engulfed by neutrophils <i>in vivo</i> and delivered to tumor site, thus improving therapeutic efficacy and mitigating myelosuppression. First, <i>in vitro</i> analysis confirmed that reassembling of abPTX formed uniform and stable serum albumin nanoparticles (NP-abPTX) with size of 107.5 ± 2.29 nm and reserved the ability to kill tumor cells. Second, we found that NP-abPTX could be engulfed by activated neutrophil <i>in vitro</i> and <i>in vivo</i> but do not affect neutrophils' function, such as chemotaxis and activation. In a murine tumor model, we further proved that local radiotherapy (RT) induced inflammation activated peripheral neutrophils to capture venous infused NP-abPTX and carry them into tumor tissue. As compared to abPTX, infusion of NP-abPTX dramatically enhanced inhibition of tumor growth treated by local RT and mitigated hematotoxicity. Therefore, our study demonstrated a novel strategy to mitigate side-effects and to improve tumor killing efficacy of abPTX through neutrophil-mediated targeting drug delivery.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yuxin</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Han</LastName>
            <ForeName>Lulu</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Xiaoyan</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Meng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Zheng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xin</LastName>
            <ForeName>Yong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lv</LastName>
            <ForeName>Yanfang</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Ankang</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Animal Laboratory, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chai</LastName>
            <ForeName>Dafei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Liantao</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Huizhong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Junnian</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Gang</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0001-6020-7263</Identifier>
            <AffiliationInfo>
              <Affiliation>Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Drug Deliv</MedlineTA>
        <NlmUniqueID>9417471</NlmUniqueID>
        <ISSNLinking>1071-7544</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000068196">Albumin-Bound Paclitaxel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>P88XT4IS4D</RegistryNumber>
          <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000068196" MajorTopicYN="Y">Albumin-Bound Paclitaxel</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Albumin-bound paclitaxel (abPTX)</Keyword>
        <Keyword MajorTopicYN="N">NP-abPTX</Keyword>
        <Keyword MajorTopicYN="N">myelosuppression</Keyword>
        <Keyword MajorTopicYN="N">neutrophil-mediated drug delivery</Keyword>
        <Keyword MajorTopicYN="N">radiotherapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors report no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>4</Day>
          <Hour>12</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35244505</ArticleId>
        <ArticleId IdType="pmc">PMC8903760</ArticleId>
        <ArticleId IdType="doi">10.1080/10717544.2022.2046892</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bokoch G, Zhao T. (2006). Regulation of the phagocyte NADPH oxidase by Rac GTPase. Antioxid Redox Signal
8:1533–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16987009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinkmann V, Reichard U, Goosmann C, et al.  (2004). Neutrophil extracellular traps kill bacteria. Science
303:1532–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15001782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu D, Dong X, Zhao Q, et al.  (2017). Photosensitization priming of tumor microenvironments improves delivery of nanotherapeutics via neutrophil infiltration. Adv Mater
29:1701021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5510494</ArticleId>
            <ArticleId IdType="pubmed">28504320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chu D, Gao J, Wang Z. (2015). Neutrophil-mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection. ACS Nano
9:11800–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4699556</ArticleId>
            <ArticleId IdType="pubmed">26516654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutiérrez Millán C, Colino Gandarillas C, Sayalero Marinero M, Lanao J. (2012). Cell-based drug-delivery platforms. Ther Deliv
3:25–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22833931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hao J, Chen J, Wang M. (2020). Neutrophils, as "Trojan horses", participate in the delivery of therapeutical PLGA nanoparticles into a tumor based on the chemotactic effect. Drug Deliv
27:1–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6920705</ArticleId>
            <ArticleId IdType="pubmed">31818156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Joerger M. (2016). Treatment regimens of classical and newer taxanes. Cancer Chemother Pharmacol
77:221–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26589792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ju C, Wen Y, Zhang L, et al.  (2019). Neoadjuvant chemotherapy based on abraxane/human neutrophils cytopharmaceuticals with radiotherapy for gastric cancer. Small
15:e1804191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30549431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li YJ, Wu JY, Liu J, et al.  (2021). From blood to brain: blood cell-based biomimetic drug delivery systems. Drug Deliv
28:1214–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8259840</ArticleId>
            <ArticleId IdType="pubmed">34142628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naumenko V, Nikitin A, Garanina A, et al.  (2020). Neutrophil-mediated transport is crucial for delivery of short-circulating magnetic nanoparticles to tumors. Acta Biomater
104:176–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31945505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierige F, Serafini S, Rossi L, Magnani M. (2008). Cell-based drug delivery. Adv Drug Deliv Rev
60:286–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17997501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramadori G, Cameron S. (2010). Effects of systemic chemotherapy on the liver. Ann Hepatol
9:133–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20526005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowinsky E, Donehower R. (1995). Paclitaxel (taxol). N Engl J Med
332:1004–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7885406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith J. (1994). Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol
56:672–86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7996043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Snyder J, Nettles J, Cornett B, et al.  (2001). The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A
98:5312–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC33206</ArticleId>
            <ArticleId IdType="pubmed">11309480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Socinski M, Manikhas G, Stroyakovsky D, et al.  (2010). A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol
5:852–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20521351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Y, Xie Z, Kim GB, et al.  (2015). Design strategies and applications of circulating cell-mediated drug delivery systems. ACS Biomater Sci Eng
1:201–17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4428174</ArticleId>
            <ArticleId IdType="pubmed">25984572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Superfin D, Iannucci AA, Davies AM. (2007). Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Oncologist
12:1070–83.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17914077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeshima T, Pop LM, Laine A, et al.  (2016). Key role for neutrophils in radiation-induced antitumor immune responses: potentiation with G-CSF. Proc Natl Acad Sci U S A
113:11300–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5056034</ArticleId>
            <ArticleId IdType="pubmed">27651484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan H, Hu J, Liu S. (2019). Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis. Artif Cells Nanomed Biotechnol
47:268–77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30600739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Timmerman R, Paulus R, Galvin J, et al.  (2010). Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA
303:1070–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2907644</ArticleId>
            <ArticleId IdType="pubmed">20233825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villanueva MT. (2017). Chemotherapy: neutrophils deliver the goods. Nat Rev Cancer
17:454–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28740115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang G, Cao L, Liu X, et al.  (2016). Oxidant sensing by TRPM2 inhibits neutrophil migration and mitigates inflammation. Dev Cell
38:453–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5455786</ArticleId>
            <ArticleId IdType="pubmed">27569419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Li J, Cho J, Malik A. (2014). Prevention of vascular inflammation by nanoparticle targeting of adherent neutrophils. Nat Nanotechnol
9:204–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4100792</ArticleId>
            <ArticleId IdType="pubmed">24561355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xue J, Zhao Z, Zhang L, et al.  (2017). Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat Nanotechnol
12:692–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28650441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yaromina A, Krause M, Baumann M. (2012). Individualization of cancer treatment from radiotherapy perspective. Mol Oncol
6:211–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5528361</ArticleId>
            <ArticleId IdType="pubmed">22381063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu H, Yang Z, Li F, et al.  (2020). Cell-mediated targeting drugs delivery systems. Drug Deliv
27:1425–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7594730</ArticleId>
            <ArticleId IdType="pubmed">33096949</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
